FindTrial
Sign In

Role of Vitamin D as an added therapy for type 1 Diabetes Mellitus patients

Role of oral Cholecalciferol as an adjunctive therapy in Type 1 Diabetes Mellitus: A Randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/07/004739
Enrollment
52
Registered
2014-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type I Diabetes Mellitus

Interventions

Intervention1: Oral Cholecalciferol: Intervention: Oral Cholecalciferol therapy will be instituted in addition to Insulin therapy for Diabetes in Interventional arm. Drug and formulation to be used-

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of ages 1-18 years diagnosed as Type 1 DM as per standardized criteria

Exclusion criteria

Exclusion criteria: 1.Patients already on Vitamin D supplements since preceding one month 2.Patients with a)Malabsorption syndrome b) Known Immunodeficiency, HIV infection c)Urolithiasis or nephrolithiasis or nephrocalcinosis d) Chronic kidney disease e)Adrenal tumors. 3.Patients receiving steroid therapy 4. Parents not affordable to carry out self-monitoring of blood glucose at home.

Design outcomes

Primary

MeasureTime frame
Mean change in HbA1C levels from baseline at time of recruitment to the level at 6 months Timepoint: 6 months—

Secondary

MeasureTime frame
1.Mean change in Insulin requirement/day 2.Mean change in Human Glutamic Acid Decarboxylase Antibody (GAD65) titers 3.Mean change in C-peptide levels Timepoint: 0,6 months—

Countries

India

Contacts

Public ContactDr Niranjan Biswal

JIPMER

drnbiswal@yahoo.com9442528402

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026